{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:14:31Z","timestamp":1770819271887,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3050,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/mt.2008.58","type":"journal-article","created":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T18:27:54Z","timestamp":1207247274000},"page":"1041-1047","source":"Crossref","is-referenced-by-count":59,"title":["Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects"],"prefix":"10.1016","volume":"16","author":[{"given":"Ta-Chiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel D","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Martuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2008.58_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2008.58_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1038\/mt.2008.58_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/0008-5472.CAN-06-2871","article-title":"Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2008.58_bib4","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1126\/science.1121411","article-title":"Synergistic antitumor effects of immune cell-viral biotherapy","volume":"311","author":"Thorne","year":"2006","journal-title":"Science"},{"key":"10.1038\/mt.2008.58_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2008.58_bib6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2008.58_bib7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI200111537","article-title":"Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia","volume":"108","author":"He","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2008.58_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/mt.2008.58_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"Kim","year":"2001","journal-title":"Nat Med"},{"key":"10.1038\/mt.2008.58_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","article-title":"Drug insight: histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid","volume":"2","author":"Kelly","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1038\/mt.2008.58_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2008.58_bib12","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1535-7163.MCT-06-0209","article-title":"Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells","volume":"5","author":"Dowdy","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/mt.2008.58_bib13","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1158\/0008-5472.CAN-05-4048","article-title":"Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates","volume":"66","author":"Qi","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2008.58_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00428-006-0173-x","article-title":"Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation","volume":"448","author":"Piacentini","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1038\/mt.2008.58_bib15","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1073\/pnas.95.12.6791","article-title":"p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells","volume":"95","author":"Archer","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2008.58_bib16","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/sj.onc.1207830","article-title":"Histone deacetylase inhibitors upregulate death receptor 5\/TRAIL-R2 and sensitize apoptosis induced by TRAIL\/APO2-L in human malignant tumor cells","volume":"23","author":"Nakata","year":"2004","journal-title":"Oncogene"},{"key":"10.1038\/mt.2008.58_bib17","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/0008-5472.CAN-04-2440","article-title":"Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1\/2 inactivation and the generation of ceramide and reactive oxygen species","volume":"65","author":"Rahmani","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2008.58_bib18","first-page":"6328","article-title":"Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228","volume":"61","author":"Kitazono","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2008.58_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ymthe.2005.11.010","article-title":"A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells","volume":"13","author":"Okada","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.58_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/hum.2006.17.55","article-title":"Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520","volume":"17","author":"Bieler","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.58_bib21","first-page":"971","article-title":"Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo","volume":"7","author":"Vigushin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.58_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1038\/mt.2008.58_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/1078-0432.CCR-05-1132","article-title":"Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589","volume":"12","author":"Qian","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.58_bib24","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1158\/1078-0432.CCR-06-0263","article-title":"Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors","volume":"12","author":"Liu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.58_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2005.12.011","article-title":"Cell cycle inhibition by an anti-cyclin D1 antibody chemically modified for intracellular delivery","volume":"244","author":"Chen","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1038\/mt.2008.58_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jnci\/djj003","article-title":"Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication","volume":"98","author":"Aghi","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2008.58_bib27","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.onc.1209371","article-title":"Cyclin D1: polymorphism, aberrant splicing and cancer risk","volume":"25","author":"Knudsen","year":"2006","journal-title":"Oncogene"},{"key":"10.1038\/mt.2008.58_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-6-24","article-title":"The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention","volume":"6","author":"Alao","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1038\/mt.2008.58_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1541-7786.MCR-04-0070","article-title":"Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor- \u03baB\/p65 DNA binding","volume":"3","author":"Hu","year":"2005","journal-title":"Mol Cancer Res"},{"key":"10.1038\/mt.2008.58_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/viro.2001.1175","article-title":"Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions","volume":"290","author":"Song","year":"2001","journal-title":"Virology"},{"key":"10.1038\/mt.2008.58_bib31","doi-asserted-by":"crossref","first-page":"d1369","DOI":"10.2741\/ben","article-title":"Adenovirus and cell cycle control","volume":"7","author":"Ben-Israel","year":"2002","journal-title":"Front Biosci"},{"key":"10.1038\/mt.2008.58_bib32","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/1078-0432.CCR-05-1213","article-title":"Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization","volume":"12","author":"Yasui","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.58_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.04265","article-title":"Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis","volume":"6","author":"Cinatl","year":"2004","journal-title":"Neoplasia"},{"key":"10.1038\/mt.2008.58_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/hum.2005.16.765","article-title":"Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma","volume":"16","author":"Benencia","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.58_bib35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-06-3145","article-title":"Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide","volume":"67","author":"Aghi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2008.58_bib36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/sj.mt.6300215","article-title":"Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow","volume":"15","author":"Breitbach","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.58_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1535-6108(02)00095-8","article-title":"Epigenetic changes in tumor Fas levels determine immune escape and response to therapy","volume":"2","author":"Maecker","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1038\/mt.2008.58_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-3-30","article-title":"The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses","volume":"3","author":"Moreira","year":"2003","journal-title":"BMC Cancer"},{"key":"10.1038\/mt.2008.58_bib39","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.molimm.2004.09.030","article-title":"Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes","volume":"42","author":"Magner","year":"2005","journal-title":"Mol Immunol"},{"key":"10.1038\/mt.2008.58_bib40","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1128\/JVI.77.23.12671-12678.2003","article-title":"Herpes simplex virus 1 gene expression is accelerated by inhibitors of histone deacetylases in rabbit skin cells infected with a mutant carrying a cDNA copy of the infected-cell protein no. 0","volume":"77","author":"Poon","year":"2003","journal-title":"J Virol"},{"key":"10.1038\/mt.2008.58_bib41","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1128\/JVI.80.7.3360-3368.2006","article-title":"ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells","volume":"80","author":"Miller","year":"2006","journal-title":"J Virol"},{"key":"10.1038\/mt.2008.58_bib42","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.0400567101","article-title":"Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity","volume":"101","author":"Chang","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2008.58_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","article-title":"Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma","volume":"5","author":"Adusumilli","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1038\/mt.2008.58_bib44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.gt.3302517","article-title":"Combination of gemcitabine and Ad5\/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer","volume":"12","author":"Raki","year":"2005","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2008.58_bib45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ymthe.2006.07.011","article-title":"Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy","volume":"14","author":"Liu","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.58_bib46","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1158\/1078-0432.CCR-04-0081","article-title":"Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12","volume":"10","author":"Wong","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.58_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.mt.6300023","article-title":"VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth","volume":"15","author":"Yoo","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.58_bib48","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/jnci\/djm229","article-title":"Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy","volume":"99","author":"Kurozumi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2008.58_bib49","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2008.58_bib50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/JVI.56.2.558-570.1985","article-title":"Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4","volume":"56","author":"DeLuca","year":"1985","journal-title":"J Virol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616317282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616317282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T20:10:58Z","timestamp":1588536658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616317282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1525001616317282"],"URL":"https:\/\/doi.org\/10.1038\/mt.2008.58","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}